An Evaluation of the Impact of Single Doses of LY3154207 on Sleep Latency in Sleep-Deprived Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs LY 3154207 (Primary) ; Modafinil
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 17 Dec 2015 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.